Literature DB >> 33483255

Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.

Emily C Daykin1, Emory Ryan1, Ellen Sidransky2.   

Abstract

Gaucher disease (GD), resulting from biallelic mutations in the gene GBA1, is a monogenic recessively inherited Mendelian disorder with a wide range of phenotypic presentations. The more severe forms of the disease, acute neuronopathic GD (GD2) and chronic neuronopathic GD (GD3), also have a continuum of disease severity with an overlap in manifestations and limited genotype-phenotype correlation. In very young patients, assigning a definitive diagnosis can sometimes be challenging. Several recent studies highlight specific features of neuronopathic GD that may provide diagnostic clues. Distinguishing between the different GD types has important therapeutic implications. Currently there are limited treatment options specifically for neuronopathic GD due to the difficulty in delivering therapies across the blood-brain barrier. In this work, we present both classic and newly appreciated aspects of the Gaucher phenotype that can aid in discriminating between acute and chronic neuronopathic GD, and highlight the continuing therapeutic challenges. Published by Elsevier Inc.

Entities:  

Keywords:  GBA1; Gaucher disease; Glucocerebrosidase; Neuronopathic; Newborn screening; Next-generation sequencing

Mesh:

Substances:

Year:  2021        PMID: 33483255      PMCID: PMC7884077          DOI: 10.1016/j.ymgme.2021.01.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  152 in total

1.  Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with Mucopolysaccharidosis type VII.

Authors:  Quoc-Hung Nguyen; Russell G Witt; Bowen Wang; Carlo Eikani; Jeremy Shea; Lucas K Smith; Gabrielle Boyle; Jaclyn Cadaoas; Renan Sper; John D MacKenzie; Saul Villeda; Tippi C MacKenzie
Journal:  Sci Transl Med       Date:  2020-02-26       Impact factor: 17.956

2.  Delivery of Glucosylceramidase Beta Gene Using AAV9 Vector Therapy as a Treatment Strategy in Mouse Models of Gaucher Disease.

Authors:  Sichen Du; Huayuan Ou; Renjie Cui; Nan Jiang; Meiqin Zhang; Xiaorong Li; Jing Ma; Jin Zhang; Duan Ma
Journal:  Hum Gene Ther       Date:  2018-10-16       Impact factor: 5.695

3.  Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease.

Authors:  Nahid Tayebi; Barbara K Stubblefield; Joseph K Park; Eduard Orvisky; Jamie M Walker; Mary E LaMarca; Ellen Sidransky
Journal:  Am J Hum Genet       Date:  2003-02-13       Impact factor: 11.025

4.  Glucocerebrosidase mutation H255Q appears to be exclusively in cis with D409H: structural implications.

Authors:  J Vithayathil; G Gibney; A D Baxevanis; B K Stubblefield; E Sidransky; N Tayebi
Journal:  Clin Genet       Date:  2009-05       Impact factor: 4.438

5.  CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.

Authors:  Thomas A Burrow; Ying Sun; Carlos E Prada; Laurie Bailey; Wujuan Zhang; Amanda Brewer; Steve W Wu; Kenneth D R Setchell; David Witte; Mitchell B Cohen; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2014-09-02       Impact factor: 4.797

Review 6.  Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene.

Authors:  E Sidransky; D M Sherer; E I Ginns
Journal:  Pediatr Res       Date:  1992-10       Impact factor: 3.756

7.  The saccadic and neurological deficits in type 3 Gaucher disease.

Authors:  William Benko; Markus Ries; Edythe A Wiggs; Roscoe O Brady; Raphael Schiffmann; Edmond J Fitzgibbon
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

8.  Bilateral Femoral Osteolytic Lesions in a Patient with Type 3 Gaucher Disease.

Authors:  Enock Teefe; Jenny Kim; Grisel Lopez; Ellen Sidransky
Journal:  Mol Genet Metab Rep       Date:  2015-12-01

9.  Previously unrecognized behavioral phenotype in Gaucher disease type 3.

Authors:  Magy Abdelwahab; Michael Potegal; Elsa G Shapiro; Igor Nestrasil
Journal:  Neurol Genet       Date:  2017-05-23

10.  Corrective surgery for kyphosis in a case of Gaucher's disease without history of vertebral compression fractures.

Authors:  Kenyu Ito; Noriaki Kawakami; Taichi Tsuji; Tetsuya Ohara; Toshiki Saito; Ryoji Tauchi; Kazuaki Morishita
Journal:  Spine Surg Relat Res       Date:  2017-11-27
View more
  3 in total

1.  Rare Diseases in Glycosphingolipid Metabolism.

Authors:  Hongwen Zhou; Zhoulu Wu; Yiwen Wang; Qinyi Wu; Moran Hu; Shuai Ma; Min Zhou; Yan Sun; Baowen Yu; Jingya Ye; Wanzi Jiang; Zhenzhen Fu; Yingyun Gong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  A rare cause of hydrops fetalis in two Gaucher disease type 2 patients with a novel mutation.

Authors:  Sebile Kılavuz; Murat Basaranoglu; Serdar Epcacan; Derya Bako; Arife Ozer; Yasemin Nuran Donmez; Emine Ipek Ceylan; Ajlan Tukun; Serdar Ceylaner; Hadi Geylani; Halise Neslihan Onenli Mungan
Journal:  Metab Brain Dis       Date:  2022-03-07       Impact factor: 3.584

3.  Newborn screening for Gaucher disease in Japan.

Authors:  Takaaki Sawada; Jun Kido; Keishin Sugawara; Shinichiro Yoshida; Shirou Matsumoto; Tomoyuki Shimazu; Yuki Matsushita; Takahito Inoue; Shinichi Hirose; Fumio Endo; Kimitoshi Nakamura
Journal:  Mol Genet Metab Rep       Date:  2022-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.